Viewing Study NCT01383759

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:59 PM
Ignite Modification Date: 2026-01-22 @ 2:30 PM
Study NCT ID: NCT01383759
Status: COMPLETED
Last Update Posted: 2020-04-07
First Post: 2011-06-27
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Light Chain Deposition Disease (LCDD or MIDD) View
None Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) View
None Monoclonal Immunoglobulin Deposition Disease (MIDD) View
None Amyloidosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None BORTEZOMIB (VELCADE) View
None CYCLOPHOSPHAMIDE (CYTOXAN) View
None DEXAMETHASONE View
None MELPHALAN View
None 11-061 View